Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy

Gene Therapy

Volumn 20, Issue 5, 2013, Pages 575-580

  Zhang, L ^a   Yu, Z ^a   Muranski, P ^b   Palmer, D C ^a   Restifo, N P ^a   Rosenberg, S A ^a   Morgan, R A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RETROVIRUS VECTOR; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA2; TUMOR ANTIGEN; TYROSINASE RELATED PROTEIN 1;

ANIMAL CELL; ARTICLE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ENGINEERING; CELL TRANSFER; ENZYME INHIBITION; IN VITRO STUDY; IN VIVO STUDY; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; WESTERN BLOTTING;

ANIMALS; ANTIGEN-PRESENTING CELLS; APOPTOSIS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; GENETIC ENGINEERING; GENETIC VECTORS; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; IMMUNOTHERAPY; MELANOMA, EXPERIMENTAL; MICE; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RECOMBINANT FUSION PROTEINS; RETROVIRIDAE; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TRANSFORMING GROWTH FACTOR BETA; TREATMENT OUTCOME;

EID: 84877788719     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2012.75     Document Type: Article

References (0)